Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
9
×
life sciences
national blog main
raleigh-durham blog main
9
×
raleigh-durham top stories
boston blog main
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
clinical trials
eli lilly
fda
merck
novartis
biogen
diagnostics
medicare
migraine research foundation
pfizer
purdue pharma
roche
What
drug
9
×
new
bio
roundup
approval
decades
fda
migraine
won
acquisitions
biggest
ceo
class
drugs
patients
pricing
thanks
acute
addresses
administration
advanced
advantages
albert
amgen
angry
anti
arguments
arrival
award
bar
benefited
big
bourla
brings
build
buy
cancer
candidates
causes
cholesterol
Language
unset
unknown
Current search:
amgen
×
drug
×
" raleigh-durham blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines